Finance

Lists
Outlook: 20.8% bullish·33.3% bearish
Go to analysis
BSX:NYSE
Boston Scientific Corp
US$42,73
+1,64%
(+0,69) 1D
US$42,62
-0,27% (-0,11)
After hours
Closed: 9 ຕ.ລ., 16 ໂມງ 0 ນາທີ 07 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BSX...
Open
US$42,12
High
US$42,83
Low
US$41,97
Mkt. cap
61,93 ຕື້
Avg. vol.
19,77 ລ້ານ
Volume
13,04 ລ້ານ
P/E ratio
17,33
52-wk high
US$105,65
52-wk low
US$41,38
EPS
US$2,47
Beta
0,58
Shares outstanding
1,45 ຕື້
No. of employees
59 ພັນ
Open
US$42,12
High
US$42,83
Low
US$41,97
Mkt. cap
61,93 ຕື້
Avg. vol.
19,77 ລ້ານ
Volume
13,04 ລ້ານ
P/E ratio
17,33
52-wk high
US$105,65
52-wk low
US$41,38
EPS
US$2,47
Beta
0,58
Shares outstanding
1,45 ຕື້
No. of employees
59 ພັນ
News stories
From web sources and news partners
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp
CEOMichael F. Mahoney
Employees59 ພັນ
Founded29 ມິ.ຖ. 1979
HeadquartersMarlborough, ມາຊາຊູເຊັດ, ສະຫະລັດ
SectorMedical device
Analyst ratings
Based on 23 analysts giving stock ratings to BSX in the past 3 months
Strong buy
Buy
19
Hold
4
Sell
0
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for BSX in the last 3 months.
Highest
Current US$42,73
US$70,00 (+63,82%)
Average
US$57,76 (+35,17%)
Lowest
US$48,00 (+12,33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Christopher Pasquale
Barclays
Hold
Initiated
US$48,00
+12,3%
10/07/2026
Matt Miksic
Barclays
Hold
Maintained
US$48,00
+12,3%
10/07/2026
Joanne Wuensch
Citi
Hold
Reiterated
US$48,00
+12,3%
10/05/2026
Unknown Analyst
Bernstein
Buy
Reiterated
US$54,00
+26,4%
10/02/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
US$56,00
+31,1%
10/01/2026
Kendall Au
RBC Capital
Buy
Maintained
US$70,00
+63,8%
10/01/2026
Larry Biegelsen
Wells Fargo
Hold
Reiterated
US$48,00
+12,3%
09/24/2026
Suraj Kalia
Oppenheimer
Buy
Reiterated
US$65,00
+52,1%
09/21/2026
Travis Steed
Bank of America Securities
Buy
Maintained
US$54,00
+26,4%
09/20/2026
Josh Jennings
TD Cowen
Buy
Maintained
US$56,00
+31,1%
09/17/2026
Matthew Taylor
Jefferies
Buy
Maintained
US$60,00
+40,4%
09/11/2026
Richard Newitter
Truist Financial
Buy
Maintained
-
-
09/09/2026
Marie Thibault
BTIG
Buy
Reiterated
US$56,00
+31,1%
09/09/2026
David Toung
Argus Research
Hold
Downgraded
-
-
07/30/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
US$60,00
+40,4%
07/31/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
US$55,00
+28,7%
07/30/2026
Pito Chickering
Deutsche Bank
Buy
Maintained
US$60,00
+40,4%
07/30/2026
David Rescott
Robert W. Baird
Buy
Maintained
US$56,00
+31,1%
07/30/2026
William Plovanic
Canaccord Genuity
Buy
Reiterated
US$66,00
+54,5%
07/30/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
US$70,00
+63,8%
07/29/2026
Mike Kratky
Leerink Partners
Buy
Maintained
US$60,00
+40,4%
07/30/2026
Michael Matson
Needham
Buy
Maintained
US$57,00
+33,4%
07/29/2026
Patrick Wood
UBS
Buy
Maintained
US$67,00
+56,8%
07/30/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
US$60,00
+40,4%
07/29/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
US$85,00
+98,9%
07/27/2026
David Roman
Goldman Sachs
Buy
Maintained
US$57,00
+33,4%
07/14/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
US$65,00
+52,1%
06/12/2026
Stephanie Elghazi
Bank of America Securities
Buy
Maintained
US$68,00
+59,1%
06/09/2026
Michael Polark
Wolfe Research
Hold
Downgraded
-
-
05/29/2026
Hans Engel
Erste Group
Hold
Reiterated
-
-
04/01/2026
Jayson Bedford
Raymond James
Buy
Maintained
US$88,00
+105,9%
03/27/2026
Danielle Antalffy
UBS
Buy
Reiterated
US$105,00
+145,7%
03/17/2026
Lee Hambright
Bernstein
Buy
Maintained
US$112,00
+162,1%
02/05/2026
Last report
29 ກ.ລ. 2026
Fiscal period
Q2 2026
US$0,86 / US$0,83
+3,86%beat
Revenue / Est. (USD)
5,44 ຕື້ / 5,37 ຕື້
+1,42%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
5,06 ຕື້
5,29 ຕື້
5,20 ຕື້
5,44 ຕື້
Cost of goods sold
1,54 ຕື້
1,61 ຕື້
1,60 ຕື້
1,61 ຕື້
Cost of revenue
1,54 ຕື້
1,61 ຕື້
1,60 ຕື້
1,61 ຕື້
Research and development expenses
514,00 ລ້ານ
569,00 ລ້ານ
516,00 ລ້ານ
554,00 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,74 ຕື້
1,83 ຕື້
1,78 ຕື້
1,80 ຕື້
Operating expense
2,48 ຕື້
2,63 ຕື້
2,53 ຕື້
2,59 ຕື້
Total operating expenses
4,02 ຕື້
4,24 ຕື້
4,13 ຕື້
4,20 ຕື້
Operating income
1,05 ຕື້
1,04 ຕື້
1,07 ຕື້
1,25 ຕື້
Other non operating income
-16,00 ລ້ານ
28,00 ລ້ານ
28,00 ລ້ານ
-6,00 ລ້ານ
EBT including unusual items
938,00 ລ້ານ
700,00 ລ້ານ
1,16 ຕື້
1,06 ຕື້
EBT excluding unusual items
935,00 ລ້ານ
1,01 ຕື້
999,00 ລ້ານ
1,14 ຕື້
Income tax expense
183,00 ລ້ານ
30,00 ລ້ານ
-176,00 ລ້ານ
155,00 ລ້ານ
Effective tax rate
19,51%
4,29%
-15,13%
14,62%
Other operating expenses
-
-
-
-
Net income
755,00 ລ້ານ
672,00 ລ້ານ
1,34 ຕື້
907,00 ລ້ານ
Net profit margin
14,91%
12,71%
25,77%
16,67%
Earnings per share
0,75
0,80
0,80
0,86
Interest and investment income
-
29,00 ລ້ານ
-
11,00 ລ້ານ
Interest expense
-87,00 ລ້ານ
-90,00 ລ້ານ
-90,00 ລ້ານ
-96,00 ລ້ານ
Net interest expenses
-87,00 ລ້ານ
-61,00 ລ້ານ
-90,00 ລ້ານ
-85,00 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
1,39 ຕື້
1,41 ຕື້
1,42 ຕື້
1,60 ຕື້
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
ແອັບຂອງ Google